Who is sponsoring NCT03729908?

NCT03729908 is sponsored by Swiss Tropical & Public Health Institute.

What drugs are being tested in NCT03729908?

Interventions in NCT03729908: Animal assisted mindfulness based intervention, Anti-stress program.

What condition does NCT03729908 study?

NCT03729908 studies Acquired Brain Injury.

Is NCT03729908 still recruiting?

NCT03729908 is currently completed. Last updated 4 March 2020.

Last reviewed 2020-03-04 · How we verify

NCT03729908: AAMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Animal Assisted Mindfulness Intervention (AAMI) for Patients With Acquired Brain Injury

Completed NA Last updated 4 March 2020

What this trial tests

NA trial testing Animal assisted mindfulness based intervention in Acquired Brain Injury in 31 participants. Completed in 12 September 2019.

Timeline

1 June 2018

Primary endpoint
12 September 2019

12 September 2019

Quick facts

Lead sponsor	Swiss Tropical & Public Health Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	31
Start date	1 June 2018
Primary completion	12 September 2019
Estimated completion	12 September 2019
Sites	1 location across Switzerland

Drugs / interventions tested

Animal assisted mindfulness based intervention
Anti-stress program

Conditions studied

Acquired Brain Injury — all drugs for Acquired Brain Injury →

Sponsor

Swiss Tropical & Public Health Institute

Who can join

18 and older, any sex, with Acquired Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the effect of an animal assisted mindfulness intervention (AAMI) on patients with acquired brain injuries on their global severity of psychological distress. In addition, the effects on the patients' symptoms of depression, anxiety, perceived stress, mood, coping and mindfulness/self-compassion will be assessed. The study experimental condition consists of 6 weeks of intervention, containing 6 different modules. In every session, an animal will be present. In the control condition, the same program and same exercises will be used without the presence of or reference to animals. Sessions take place two times a week for 6 weeks (leading up to a total of 12 experimental/control sessions), each lasting for about 60 minutes. 24 participants are planned to be included, 12 patients in each group.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of animal-assisted psychotherapy incorporating mindfulness and self-compassion in neurorehabilitation: a randomized controlled feasibility trial.
Künzi P, Ackert M, Grosse Holtforth M, Hund-Georgiadis M, et al · · 2022 · cited 4× · PMID 35764668 · DOI 10.1038/s41598-022-14584-1

Verify or expand the search:

Other recruiting trials for Acquired Brain Injury

Currently open trials in the same condition.

NCT07378592 — Driving Simulator Training For Adults With Acquired Brain Injuries · NA · recruiting
NCT07435155 — ACURES: Acoustic and Respiratory Parameters for Dysarthria Assessment · recruiting
NCT07237386 — Comparing the Ceriter Stride One, a Pressure-sensitive Smart Insole, With Gait Parameters Measured on the GRAIL in Neuro · NA · recruiting
NCT06848140 — Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain Injury · NA · recruiting
NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting

Other Swiss Tropical & Public Health Institute trials

Trials by the same sponsor.

NCT06606860 — Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate Tablets · Phase 1 · completed
NCT06373835 — Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis · Phase 2 · completed
NCT06304831 — Use of Facility Ratings to Improve Satisfaction With Heath Care for Children · NA · completed
NCT05644067 — Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic C · Phase 1 · completed
NCT06648603 — Citizen Action for Sustainable Dengue Control in Sub-Saharan Africa · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03729908 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Tropical & Public Health Institute
Last refreshed: 4 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03729908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing